Articles

A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse.

Racial Differences in Abnormalities by FISH in Minorities with Multiple Myeloma: A Single-Center Experience

ASCO 2017 – Multiple Myeloma, ASCO

Conference Correspondent

This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma.

Cost-Effectiveness of Carfilzomib, Ixazomib, Elotuzumab, or Daratumumab with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM

ASCO 2017 – Multiple Myeloma, ASCO

Conference Correspondent

The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM).

The Evolution of Chemotherapy-Induced Nausea and Vomiting Management: Challenges and Opportunities

By John A. Welz, MPH

Chemotherapy, CINV Management, Personalized Medicine

June 2017, Vol 8, No 3, Supplement 2: The Evolution of Chemotherapy-Induced Nausea and Vomiting Management: Challenges and Opportunities

Highlights from Best Practices in Lung Cancer Navigation Summit

Lung Cancer

Highlights from Best Practices in Lung Cancer Navigation Summit

At the Best Practices in Lung Cancer Navigation Summit, held October 22, 2016, in Rosemont, IL, oncology nurse navigators involved in the care of patients with lung cancer convened to discuss the complexities and role of nurse navigators in the treatment of lung cancer.